SALT LAKE CITY, June 2, 2015 /PRNewswire/ -- Great Basin
Scientific, Inc. (NASDAQ: GBSN, GBSNU), a molecular diagnostics
company, today announced the election of Kirk Calhoun to its Board of Directors,
effective May 27, 2015. Mr. Calhoun
was elected to the board as an independent director during the
Company's Annual Stockholder Meeting on May
27 in Salt Lake City. He
will serve as the chair of the Company's Audit Committee. Mr.
Calhoun joins Ryan Ashton,
David Spafford, Ronald K. Labrum and Sam
Chawla on the board, and replaces Steven Aldous, who is retiring from his director
position.
"Following a broad search for a professional with experience
that would further strengthen our board's breadth of talent and
background, we are delighted to have identified such an outstanding
individual in Kirk Calhoun," said
Ryan Ashton, co-founder and Chief
Executive Officer of Great Basin. "Kirk's strong experience in
finance, corporate governance and his service on the Boards of
other life sciences companies will be extremely valuable as Great
Basin continues pursuing its growth strategy."
"On behalf of our board and the management team, I would like to
offer our sincere appreciation to Steve
Aldous for his important contributions to Great Basin during
our early growth phase," Ashton continued.
Mr. Calhoun is a Certified Public Accountant (non-practicing)
with a background in auditing and accounting. Mr. Calhoun joined
Ernst & Young LLP, a public accounting firm, in 1965 and served
as a partner of the firm from 1975 until his retirement in 2002.
Mr. Calhoun currently serves on the board and audit committee of
Response Genetics, Inc. (NASDAQ: RGDX) and Ryerson Holding
Corporation (NYSE: RYI). Mr. Calhoun has served previously on the
boards and audit committees of five public companies in the
pharmaceutical industry up until the dates of their respective
sales, including Abraxis Bioscience, Inc., Myogen, Inc., Aspreva
Pharmaceuticals Company, Replidyne, Inc. and Adams Respiratory
Therapeutics, Inc. Mr. Calhoun also currently serves on the
boards of three private companies, including NeuroSigma, Inc., a
developer of products that treat major neurological and
neuropsychiatric disorders such as epilepsy and depression. Mr.
Calhoun received a B.S. in Accounting from the University of Southern California.
About Great Basin Scientific
Great Basin Scientific is
a molecular diagnostics company that commercializes breakthrough
chip-based technologies. The Company is dedicated to the
development of simple, yet powerful, sample-to-result technology
and products that provide fast, multiple-pathogen diagnoses of
infectious diseases. The Company's vision is to make molecular
diagnostic testing so simple and cost-effective that every patient
will be tested for every serious infection, reducing misdiagnoses
and significantly limiting the spread of infectious disease. More
information can be found on the company's website at
www.gbscience.com.
Forward-Looking Statements
This press release includes
forward-looking statement regarding events, trends and business
prospects, which may affect our future operating results and
financial position. Forward-looking statements involve risk and
uncertainties, which could cause actual results to differ
materially, and reported results should not be considered as an
indication of future performance. These risk and uncertainties
include, but are not limited to: (i) our limited operating history
and history or losses; (ii) our ability to develop and
commercialize new products and the timing of commercialization;
(iii) our ability to obtain capital when needed; and (iv) other
risks set forth in the Company's filings with the Securities and
Exchange Commission, including the risks set forth in the company's
Annual Report on Form 10-K for the year ended December 31, 2014. These forward-looking
statements speak only as of the date hereof and Great Basin
Scientific specifically disclaims any obligation to update these
forward-looking statements, except as required by law.
Media Contact:
Kate Ottavio Kent
ICR
203.682.8276
Kate.Ottavio-Kent@icrinc.com
Investor Relations Contact:
Bob Yedid
ICR
646.277.1250
bob.yedid@icrinc.com
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/great-basin-welcomes-kirk-calhoun-to-board-of-directors-300092108.html
SOURCE Great Basin Scientific, Inc.
